NEOGEN Q4 FY26 earnings call NEOG

Neogen is focused on three key strategic initiatives to become the undisputed global food safety category leader. These include enhancing commercial prowess through a new go-to-market strategy, driving high-impact innovation with increased R&D investment and technology licensing, and improving operational efficiency through disciplined cost management and enterprise system upgrades. These initiatives are designed to accelerate long-term growth and profitability, with investments largely funded by cost savings.

The company is repositioning its commercial organization to align with a new go-to-market strategy, focusing on 14 priority countries and high-value accounts. This effort includes investing in e-commerce and customer service automation to serve a broader customer base, as approximately 40% of food safety revenue currently flows through e-commerce. A dedicated strategic account function is being established to engage with senior decision-makers and position enterprise-wide solutions, moving away from a product-centric approach.

Neogen plans to increase R&D investment by 50% in FY27, aiming for 5% of revenue long-term, to deliver attractive returns on invested capital. This investment focuses on next-generation platforms in core markets like pathogen detection and general sanitation, technology licensing, and expanding the Petrifilm line. A new Petrifilm innovation line at Oakdale, Minnesota, will enable the launch of two new SKUs per year and support up to five simultaneous innovation projects, with meaningful revenue contribution expected from FY29.

The multi-quarter transition of Petrifilm manufacturing is on track to begin in November 2026, with the first SKU expected to be fully validated in August 2026. This validation is considered a major de-risking event for the program, demonstrating the team's capabilities. The company anticipates 200 to 300 basis points of gross margin expansion once the line is fully ramped up, with benefits primarily realized in FY28.

Neogen is actively driving initiatives to improve profitability and reduce costs, focusing on reducing inventory write-downs, improving purchase price variance, optimizing pricing, and enhancing sample collection margins. The company has already reduced actual inventory by over $36 million year-over-year and improved on-time and full delivery performance by 40% since implementing its sales and operations planning (S&OP) process. Investments in technology and enterprise capability upgrades are also planned for FY27.

The divestiture of the Genomics business unit is awaiting regulatory approvals from Australia and New Zealand, with an expected closing by the end of H1 FY27. The $140 million in net proceeds will be used for debt paydown and business investment. This is expected to put Neogen on track to achieve a net leverage ratio below 3x by calendar year-end and close to its target range of 2.5x by the end of FY27.